Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit

According to CEO Peter Meldrum, Myriad’s strong IP position on the BRACAnalysis test and a large internal database of BRCA mutations ensure that "regardless of the outcome of this particular lawsuit, it will not have a material adverse effect on the company … or on the future revenues of our products."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.